Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Delafloxacin

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Delafloxacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 9,506Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics
    Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics

    10 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230710869070/en

    BUSINESSWIRE
    10 Jul 2023
    Share Share
    Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin
    Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin

    11 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin
    Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin

    11 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share
    Commonly used antibiotic in India under USFDA lens
    Commonly used antibiotic in India under USFDA lens

    13 Jul 2018

    // Sushmi Dey ECONOMIC TIMES

    https://health.economictimes.indiatimes.com/news/pharma/commonly-used-antibiotic-in-india-under-usfda-lens/64958016

    Sushmi Dey ECONOMIC TIMES
    13 Jul 2018
    Share Share
    FDA warning for fluoroquinolone antibiotics on risks of adverse reactions
    FDA warning for fluoroquinolone antibiotics on risks of adverse reactions

    11 Jul 2018

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=109928&sid=2

    PHARMABIZ
    11 Jul 2018
    Share Share
    Melinta Publication Highlights Baxdela Activity Against Fluoroquinolone
    Melinta Publication Highlights Baxdela Activity Against Fluoroquinolone

    25 Jun 2018

    // PRESS RELEASE

    http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-publication-highlights-baxdela-activity

    PRESS RELEASE
    25 Jun 2018
    Share Share